Valion Bio Profit Margin

Valion Bio (VBIO) currently reports a profit margin of 6328.21% as of June 2026. That compares with -1372.51% in the prior-year period — up 561.1% year over year. That is above the sector sector average of 13.78%. Use the charts on this page to explore Valion Bio's profit margin history and peer comparisons.

Valion Bio's profit margin increased from -1372.51% to 6328.21% — a 561.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Valion Bio's profit margin of 6328.21% is higher than the its sector sector average of 13.78%. That is roughly 45831.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Valion Bio's current 6328.21% should be judged against industry norms (sector average: 13.78%) and against VBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 6328.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.78%. From there, open related valuation or income-statement pages for Valion Bio, and consider following VBIO for alerts when major investors trade the stock.